Telephone: (212) 705-0496
Charles Baltic joined Needham & Company in March 2009. Charles is the Co-Head of the Investment Banking Healthcare Group. He has over 20 years of experience working with life sciences and healthcare companies in a significant variety of transactional contexts. Prior to joining Needham, Charles was a Managing Director and Head of the Biotechnology Investment Banking practice at CRT Capital Group from 2006 to 2009. From 2001 to 2006, he served as a Managing Director in Healthcare Investment Banking at Wachovia Securities (now Wells Fargo Securities) where he founded Wachovia’s Biotechnology Investment Banking practice. Prior to Wachovia, he was with Healthcare Investment Banking at Cowen and Company from 1996 – 2001. Prior to 1996, Charles practiced corporate and securities law with Dewey Ballantine. Charles currently serves on the Boards of Directors of MEI Pharma (NASDAQ: MEIP), an oncology-focused biopharmaceutical company, SIDIS Inc., a life sciences investment holding company, and Life Science Washington (formerly of the Washington Biotechnology and Biomedical Association), the trade association for the life science industry in Washington State. Charles is also a current and a founding Trustee of the Hope Funds for Cancer Research. He is a former Director of Med-Vantage Inc., a health informatics company which was acquired by IMS Health in 2011, and a former member of the U.S. Securities and Exchange Commission’s Advisory Committee on Small and Emerging Companies from 2014 -2015. He holds B.A. and J.D. degrees from Georgetown University and a MBA degree in finance from the Wharton School of the University of Pennsylvania.
Telephone: (212) 705-0378
Simon Gill rejoined Needham & Company in January 2010 as Co-Head of the Investment Banking Healthcare Group, having been a senior banker at the firm in 2003 - 2006. He has over 30 years of investment banking experience, working primarily with U.S. as well as Canadian, European and Israeli healthcare companies. He has been involved in over 400 transactions in his career, and in the last ten years has completed over 100 financing and M&A transactions for healthcare companies. Prior to rejoining Needham, Simon was Co-head of U.S. Healthcare Investment Banking at RBC Capital Markets. He began his career with Credit Suisse First Boston in London in 1982. He has worked in the U.S. since 1984, mainly focused on providing financial advisory and capital raising services for U.S. healthcare companies. In addition to RBC and CSFB, he has worked at SBC Warburg (now called UBS), Schroders, Inc. and Prudential Securities, where he was Head of Investment Banking. Simon graduated from the University of Oxford in 1982 with MA and BA degrees.
Telephone: (212) 705-0342
Dan Cocks joined Needham & Company in March 2011. Dan has extensive experience working with life science companies across a variety of transactional settings, closing over 50 equity transactions and helping to bring over 20 companies public in the biotechnology, specialty pharmaceutical and medical technology sectors. Prior to joining Needham, Dan worked in Citi's Global Transaction Services division. He graduated from the Boston College Carroll School of Management Honors Program with a Bachelor of Science in Management and concentrations in finance and accounting.
Leadership | China Investment Banking | Clean Technology | Communications | Enterprise Infrastructure | Financial Services | Healthcare | Industrial & Diversified Growth | Internet, Digital Media & Consumer | Israeli Investment Banking | Semiconductors & Semiconductor Equipment | Software & Services | Mergers & Acquisitions | Private Capital Markets | Capital Markets